Showing results (181-190 of 188) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 188 results.
Arthritis & Rheumatology (Hoboken, N.J.)|December 9, 2025
Distinct natural killer cell signature in still's disease: Insights from a multinational immunome project consortium for autoinflammatory disordersAmber De Visscher, Jarne Beliën, Bert Malengier-Devlies, et al.
The Journal of Experimental Medicine|March 26, 2024
Functional diversity of NLRP3 gain-of-function mutants associated with CAPS autoinflammationCamille Cosson, Romane Riou, Danish Patoli, et al.
Annals of the Rheumatic Diseases|September 24, 2024
EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's diseaseBruno Fautrel, Stéphane Mitrovic, Arianna De Matteis, et al.
EMBO Molecular Medicine|June 17, 2026
Systems serology identifies FcR-related autoantibody signatures and functions for Sjögren's syndromeMartin Killian, Suzanne K Shoffner-Beck, Timon Damelang, et al.
Chest|October 22, 2022
Pleuropulmonary Manifestations of Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) SyndromeRaphael Borie, Marie Pierre Debray, Alexis F Guedon, et al.
Cell Reports|July 21, 2021
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STINGMarine Bruand, David Barras, Marco Mina, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 11, 2025
American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert PanelArsene M Mekinian, Sophie Georgin-Lavaille, Marcela A Ferrada, et al.
Annals of the Rheumatic Diseases|May 22, 2024
Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEXJerome Hadjadj, Yann Nguyen, Dalila Mouloudj, et al.
Pageof 19